10-Year Survival and Quality of Life in Patients With High-Risk PN0 Prostate Cancer Following Definitive Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 4, 2007, Pages 1074-1083

  Berg, Arne ^a   Lilleby, Wolfgang ^b   Bruland, Øyvind Sverre ^a,b   Fosså, Sophie Dorothea ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adverse effects; Lymphadenectomy; Prostate cancer; Quality of life; Radiotherapy

Indexed keywords

HORMONES; MEDICAL PROBLEMS; RADIOTHERAPY;

BOWEL FUNCTION; CLINICAL PROGRESSION; GLEASON SCORES; LYMPHADENECTOMY; QUALITY OF LIFE;

ONCOLOGY;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROGRESSION FREE SURVIVAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LYMPH NODE NEGATIVE STAGE PROSTATE CANCER; LYMPHADENECTOMY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NORWAY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; URINATION DISORDERS;

EID: 35448994486     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.031     Document Type: Article

References (41)

1. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 13 360 (2002) 103-106
2. Ganswindt U., Paulsen F., Anastasiadis A.G., et al. 70 Gy or more: Which dose for which prostate cancer?. J Cancer Res Clin Oncol 131 (2005) 407-419
3. Kupelian P.A., Buchsbaum J.C., Patel C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52 3 (2002) 704-711
4. Fossa S.D., Lilleby W., Waehre H., et al. Definitive radiotherapy of prostate cancer: The possible role of staging lymphadenectomy. Int J Radiat Oncol Biol Phys 57 (2003) 33-41
5. Lilleby W., Torlakovic G., Torlakovic E., et al. Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy. Cancer 92 (2001) 311-319
6. Mostofi F.K., Davis Jr. C.J., and Sesterhenn I.A. Pathology of carcinoma of the prostate. Cancer 70 Suppl. 1 (1992) 235-253
7. Lilleby W., Fossa S.D., Waehre H.R., and Olsen D.R. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 43 (1999) 735-743
8. O'Leary M.P., Fowler F.J., Lenderking W.R., et al. A brief male sexual function inventory for urology. Urology 46 (1995) 697-706
9. Litwin M.S., Hays R.D., Fink A., et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 36 (1998) 1002-1012
10. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
11. Bjordal K., de G.A., Fayers P.M., et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0. and the head and neck cancer specific module (EORTC QLQ-H&N35. in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36 14 (2000) 1796-1807
12. Hjermstad M.J., Fayers P.M., Bjordal K., and Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). J Clin Oncol 16 (1998) 1188-1196
13. Litwin M.S. Health related quality of life in older men without prostate cancer. J Urol 161 (1999) 1180-1184
14. Mykletun A., Dahl A.A., O'Leary M.P., and Fossa S.D. Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int 97 (2006) 316-323
15. O'Leary M.P., Rhodes T., Girman C.J., et al. Distribution of the Brief Male Sexual Inventory in community men. Int J Impot Res 15 (2003) 185-191
16. Osoba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998) 139-144
17. Edwards N.I., and Jones D. The prevalence of faecal incontinence in older people living at home. Age Ageing 30 (2001) 503-507
18. Goode P.S., Burgio K.L., Halli A.D., et al. Prevalence and correlates of fecal incontinence in community-dwelling older adults. J Am Geriatr Soc 53 (2005) 629-635
19. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. J Urol 168 (2002) 514-518
20. Gervasi L.A., Mata J., Easley J.D., et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142 2 Pt 1 (1989) 332-336
21. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 25 (2003) 2491-2499
22. Zagars G.K., von Eschenbach A.C., Johnson D.E., and Oswald M.J. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 60 (1987) 1489-1499
23. Roach M., Lu J., Pilepich M.V., et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47 (2000) 609-615
24. Perez C.A., Michalski J., and Lockett M.A. Radiation therapy in the treatment of localized prostate cancer: An alternative to an emerging consensus. Mo Med 92 11 (1995) 696-704
25. Zietman A.L., Coen J.J., Dallow K.C., and Shipley W.U. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int J Radiat Oncol Biol Phys 32 (1995) 287-292
26. Weingartner K., Ramaswamy A., Bittinger A., et al. Anatomical basis for pelvic lymphadenectomy in prostate cancer: Results of an autopsy study and implications for the clinic. J Urol 156 (1996) 1969-1971
27. DiMarco D.S., Zincke H., Sebo T.J., et al. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121-1125
28. Stone N.N., Stock R.G., and Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 158 (1997) 1891-1894
29. Berg A., Berner A., Lilleby W., et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 120 (2007) 1603-1609
30. Bostwick D.G., and Foster C.S. Predictive factors in prostate cancer: Current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 17 (1999) 222-272
31. Chuba P.J., Moughan J., Forman J.D., et al. The 1989 patterns of care study for prostate cancer: five-year outcomes. Int J Radiat Oncol Biol Phys 50 (2001) 325-334
32. Bhatnagar V., Stewart S.T., Huynh V., et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis 9 (2006) 136-146
33. Sprangers M.A., and Schwartz C.E. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 48 11 (1999) 1507-1515
34. Korfage I.J., Essink-Bot M.L., Borsboom G.J., et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 116 (2005) 291-296
35. Krahn M., Ritvo P., Irvine J., et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 41 (2003) 153-164
36. Kumar S., Shelley M., Harrison C., et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4 (2006) CD006019
37. Lilleby W., Fossa S.D., Knutsen B.H., et al. Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol 57 (2000) 195-200
38. Hanlon A.L., Pinover V.H., Horwitz E.M., and Hanks G.E. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Biol Phys 50 (2001) 845-849
39. Gray C.L., Powell C.R., Riffenburgh R.H., and Johnstone P.A. 20-year outcome of patients with T1-3N0 surgically staged prostate cancer treated with external beam radiation therapy. J Urol 166 (2001) 116-118
40. Asbell S.O., Martz K.L., Shin K.H., et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40 (1998) 769-782
41. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005 May 12) 1977-1984